Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
LETTER TO THE EDITOR
Year : 2019  |  Volume : 15  |  Issue : 6  |  Page : 1421

Cost–risk analysis of available cervix cancer vaccine: Situation analysis from Thailand


1 Wiwanitkit House, Bangkhae, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayo Babalola University, Ilesa, Osun, Nigeria

Date of Submission24-Jun-2018
Date of Decision16-Feb-2019
Date of Acceptance11-May-2019
Date of Web Publication24-Dec-2019

Correspondence Address:
Dr. Somsri Wiwanitkit
Joseph Ayo Babalola University, Ilesa, Osun
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_415_18

Rights and Permissions

How to cite this article:
Wiwanitkit S, Wiwanitkit V. Cost–risk analysis of available cervix cancer vaccine: Situation analysis from Thailand. J Can Res Ther 2019;15:1421

How to cite this URL:
Wiwanitkit S, Wiwanitkit V. Cost–risk analysis of available cervix cancer vaccine: Situation analysis from Thailand. J Can Res Ther [serial online] 2019 [cited 2022 Aug 19];15:1421. Available from: https://www.cancerjournal.net/text.asp?2019/15/6/1421/273854



Sir,

Cervix cancer is an important female cancer that causes several deaths each year.[1] Luckily, the new vaccine against cervix cancer is already developed and in use.[2] In Thailand, the cervix cancer is also highly prevalent and becomes the leading cause of death among local female, and annual screening is the basic public health policies in Thailand.[3] The introduction of the cervical cancer vaccine in Thailand becomes a new hope for control of the disease. At present, the vaccine is still expensive and its cost becomes a big consideration. Several new reports confirm for the cost-effectiveness of the vaccination of the available vaccines.[4],[5],[6],[7] The vaccine is proven cost-effective regardless commercial types of vaccine.[8] Nevertheless, the additional concern is on the adverse effect of the vaccine. There are only few reports on this issue and extremely few reports regarding the cost and risk of the vaccines. Here, the authors perform the cost and risk analysis of the available cervix cancer vaccines in Thailand – Gardasil and Cervarix. The cost identification is performed. The unit cost at the tertiary hospital in Thailand in USD is used for further analysis. Focusing on the risk, the data from a recent report on the reactogenicity of the vaccines are used for further analysis.[9] The cost–risk analysis is performed, and the result is shown in [Table 1]. Conceptually, the good vaccine should have lower cost and lower risk. For cost–risk analysis, it can be seen that Cervarix is slightly cheaper but have significantly more risk. The cost–risk analysis hereby shows that the Gardasil is more favorable.
Table 1: Cost-risk analysis of available cervix cancer vaccines in Thailand

Click here to view


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 > References Top

1.
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev 2017;26:444-57.  Back to cited text no. 1
    
2.
Harper DM, DeMars LR. HPV vaccines – A review of the first decade. Gynecol Oncol 2017;146:196-204.  Back to cited text no. 2
    
3.
Wiwanitkit V. Screening for cervical cancer, results from Thailand. Asian Pac J Cancer Prev 2006;7:329-30.  Back to cited text no. 3
    
4.
Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19.  Back to cited text no. 4
    
5.
Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, et al. A randomized, observer-blinded immunogenicity trial of cervarix(®) and gardasil(®) human papillomavirus vaccines in 12-15 year old girls. PLoS One 2013;8:e61825.  Back to cited text no. 5
    
6.
Song X, Mao F, Zhou Z, Zhao Q, Fang Y. Health economic evaluation of human papillomavirus vaccines in the developing countries: Systematic reviews. Zhonghua Yu Fang Yi Xue Za Zhi 2016;50:85-90.  Back to cited text no. 6
    
7.
Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol 2016;28:4-10.  Back to cited text no. 7
    
8.
Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol 2015;73:759-67.  Back to cited text no. 8
    
9.
Haskins-Coulter T, Southern J, Andrews N, Miller E. Reactogenicity of cervarix and gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females. Hum Vaccin Immunother 2017;13:1-9.  Back to cited text no. 9
    



 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Article Tables
  In this article
>References

 Article Access Statistics
    Viewed1365    
    Printed22    
    Emailed0    
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]